R. Borson

发表

Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.

C. Obasaju, J. Reeves, Michael Jones, 2012, Clinical breast cancer.

Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC).

D. Yardley, W. G. Harker, J. Beck, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: value of duplex sonography.

J. Brink, W. Middleton, S. Teefey, 1995, AJR. American journal of roentgenology.

Regulation of the Gene for CD 34 , a Human Hematopoietic Stem Cell Antigen , in KG1 Cells

D. Tenen, A. Satterthwaite, R. Borson, 2003 .

Regulation of the gene for CD34, a human hematopoietic stem cell antigen, in KG-1 cells.

D. Tenen, A. Satterthwaite, R. Borson, 1990, Blood.

International System for Cytogenetic Nomenclature (ISCN) — guidelines on cancer cytogenetics

R. Eddy, T. Shows, M. Schmid, 1990 .

Chromosome 1 localization of the gene for CD34, a surface antigen of human stem cells.

R. Eddy, T. Shows, D. Tenen, 1990, Cytogenetics and cell genetics.

Prophylaxis and therapy with factor VII concentrate (human) immuno, vapor heated in patients with congenital factor VII deficiency: A summary of case reports

K. Bauer, W. Zinkham, M. Kunschak, 1995, American journal of hematology.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

H. Rugo, L. Amler, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retained Hickman catheter cuff as an infection source following allogeneic bone marrow transplant.

E. Whitman, R. Borson, R. Brown, 1994, Bone marrow transplantation.

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.

M. Birkner, H. Burris, C. Vogel, 2009 .

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.

M. Birkner, H. Burris, C. Vogel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary Mediastinal Large Cell Lymphoma with Sclerosis Containing a Large Number of T Cells: Differential Diagnosis

C. Dunphy, A. Babich, R. Borson, 1999 .